(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 39.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Fennec Pharmaceuticals's revenue in 2025 is $33,302,000.On average, 2 Wall Street analysts forecast FENC's revenue for 2025 to be $1,348,445,768, with the lowest FENC revenue forecast at $1,229,047,784, and the highest FENC revenue forecast at $1,467,843,753. On average, 2 Wall Street analysts forecast FENC's revenue for 2026 to be $2,082,367,644, with the lowest FENC revenue forecast at $1,743,377,563, and the highest FENC revenue forecast at $2,421,357,726.
In 2027, FENC is forecast to generate $2,426,089,115 in revenue, with the lowest revenue forecast at $2,426,089,115 and the highest revenue forecast at $2,426,089,115.